Cromsource adds new CMO, expands medical affairs offering

Italy-based CRO Cromsource has appointed Pfizer, Novartis and Paraxel vet Dr. Grzegorz Rychlik as its new chief medical officer as it beefs up its medical affairs department.

Dr. Rychlik, who has more than a quarter of a century of biopharma experience under his belt, has worked across a number of big and small biopharmas as a medical director and CMO, and most recently was the managing director of U.K.-based MRCD Pharma Services.

Dr. Oriana Zerbini, founder and CEO of Cromsource, said: “The addition of an experienced and respected medical professional such as Greg strongly positions Cromsource to be able to further support the increasingly complex product development needs of our clients. Additionally, as we expand our medical affairs offering we will optimize and grow our consultancy and medical services to better serve our clients.”


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Dr. Troy McCall, the company’s COO, added that under their new CMO’s tenure, they will expand the company's medical monitoring, pharmacovigilance, and medical writing services “to meet growing client needs.”

He went on: “Having highly experienced and skilled individuals such as Greg within the Medical Affairs Services group will allow for the optimization and standardization of interdependent processes, while leveraging efficiencies and ensuring that the highest level of quality is delivered.”

This forms part of its broader expansion plans over the years that also saw it back in May make a glut of new appointments to its management team, as it also opened a new office in CRO heartland Research Triangle Park.

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

The Mayo Clinic tapped data analytics firm nference to build out an AI-powered engine to collate its years of clinical records and pathology work.

At the annual J.P. Morgan Healthcare Conference, major CRO Charles River Laboratories and Takeda announced a new preclinical tie-up.